C88 Categoría · se requiere mayor especificidad Malignant immunoproliferative diseases and certain other B-cell lymphomas
ICD-10-CM C88 identifies “Malignant immunoproliferative diseases and certain other B-cell lymphomas” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Instrucciones de niveles superiores
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C81-C96 · Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
Códigos más específicos
C88.0Waldenstrom macroglobulinemiaCategoría · se requiere mayor especificidadC88.2Heavy chain diseaseCategoría · se requiere mayor especificidadC88.3Immunoproliferative small intestinal diseaseCategoría · se requiere mayor especificidadC88.4Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]Categoría · se requiere mayor especificidadC88.8Other malignant immunoproliferative diseasesCategoría · se requiere mayor especificidadC88.9Malignant immunoproliferative disease, unspecifiedCategoría · se requiere mayor especificidadReferencias del índice oficial
Referencias desde otros códigos (2)
Excludes 1 · malignant neoplasm of lymph nodes, specified as primary (C81-C86, C88, C96.-)
Inclusion terms · Conditions classifiable to C88-C90, C96
Historial
Historial del código
Sin cambios desde la primera aparición
ModificadoSin cambios
FY2016
Vigente desde
- Primera aparición
Malignant immunoproliferative diseases and certain other B-cell lymphomas
Categoría — seleccione un código más específico
CDC/NCHS · FY2016Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Sin cambios tabulares |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.